Dr Charles Naltet
- Spécialité
- Oncologue médical, expert poumon
- Titre
- Responsable unité d'oncologie thoracique
- Hôpital
- Hôpital Saint-Joseph (Paris)
- Derniers articles
-
- Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial. (18 sept. 2025)
- Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. (1 mai 2025)
- Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer. (28 nov. 2024)
- Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience. (30 juil. 2024)
- Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study. (5 avr. 2024)